In the multi-center, randomized, double-blind, placebo-controlled trial, half of the enrolled women were given placebo capsules, the other half were given capsules of a safe, high purity, non-plant derived, non-allergenic, patent-protected, proprietary genistein branded as geniVida™ by DSM Nutritional Products, Inc. Study measurements included daily hot flashes (frequency, duration and intensity), individual-specific safety factors and adverse events.
According to the clinical study, presented as a poster in the “Late Breaking Abstracts” section of the meeting, women receiving 30 mg per day of geniVida™ experienced 40% fewer hot flashes after eight weeks and 44% fewer hot flashes after 12 weeks vs. baseline, which became statistically significant vs. placebo at 12 weeks. Furthermore, 88.5% of women in the geniVida™ group had a 25% or greater reduction in the duration of daily hot flashes vs. baseline at 12 weeks, also statistically significant vs. placebo. There were no differences between the groups for any of the safety factors or adverse events.
The genistein in geniVida™, formerly known as BONISTEIN®, is a branded, pure, non-soy genistein from DSM. It is available in both food- and pharmaceutical-grade and is supported by extensive, published safety studies. geniVida™ is available in both crystalline and tablet-grade forms.
DSM Nutritional Products is the world’s premier ingredient supplier to producers of functional foods, beverages, and dietary supplements. The organization provides a solid platform for technological innovation and new product development. Utilizing its extensive resources, DSM Nutritional Products keeps its customers ahead of the ever-changing marketplace, anticipating customer needs as nutritional trends develop and consumer demands evolve.